Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutikizumab in moderately to severely active ulcerative colitis
NCT06257875Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2024
- Primary completion
- Sep 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 30
01
Overview
A Phase 2 trial of lutikizumab in ulcerative colitis (UC), sponsored by AbbVie Inc.. Started Mar 2024; status: active, not recruiting.
02
Drugs
lutikizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06257875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06257875.